Lyra Therapeutics (LYRA) Restructuring Costs (2024 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Restructuring Costs of $238000.0 in Q4 2025, up 1233.33% on a QoQ basis from -$21000.0 in Q3 2025, and down 85.51% YoY from $1.6 million in Q4 2024.
Lyra Therapeutics (LYRA) Restructuring Costs (2024 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Restructuring Costs for 2 consecutive years, with $238000.0 the latest figure, recorded in Q4 2025.
- Restructuring Costs for Q4 2025 came in at $238000.0, down 85.51% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.5 million (down 86.08% YoY), and the FY2025 annual result was $1.5 million, down 86.23% from the prior year.
- Restructuring Costs for Q4 2025 stood at $238000.0, up from -$21000.0 in the prior quarter.
- The five-year high for Restructuring Costs was $6.4 million in Q2 2024, with the low at -$21000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 238,000.00 |
| Sep 30, 2025 | -21,000.00 |
| Jun 30, 2025 | 400,000.00 |
| Mar 31, 2025 | 900,000.00 |
| Dec 31, 2024 | 1.64 Mn |
| Sep 30, 2024 | 2.80 Mn |
| Jun 30, 2024 | 6.45 Mn |